Sales of the drug, which comprised nearly half of Merck’s sales last year, totaling $29.5 billion, are expected to peak ...

Adagene, Inc. (($ADAG)) announced an update on their ongoing clinical study. Study Overview: Adagene, Inc. (ADAG) is conducting a Phase 1b/2 ...

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Study Overview: Akeso, Inc. is conducting a Phase I/II study titled ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis with antibody-drug conjugates, suggest two trials presented at ESMO 2025.

The Phase III clinical study of JSKN003 for PROC is currently underway in China, while a Phase II study has been approved to initiate in the U.S. The granting of FTD by the FDA will further accelerate ...

ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences in ...

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report third-quarter 2025 results on Oct. 30, before market ...

New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for ...

Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...